

## Special Issue

# Targeting Tumor Microenvironment for Cancer Therapy

### Message from the Guest Editors

Chemotherapy is the treatment of choice for cancer, but the currently available therapeutic drugs for it have limited efficacy. Recent studies have suggested that cancer stem cells in the tumor microenvironment may play an important role in the drug resistance of chemotherapy. The tumor microenvironment comprising cellular components, such as cancer-associated fibroblasts, tumor-associated macrophages, tumor-associated neutrophils and endothelial cells, has been recognized as a critical contributor to the development and progression of cancer. As the seed and soil hypothesis states that the tumor microenvironment, as a main driver, promotes cancer stemness and therapeutic resistance in most cancers, new agents or treatment strategies that modulate the tumor microenvironment are urgently needed. Regarding this concept, the focus of this issue is investigations on new treatment strategies and molecular mechanisms of tumor microenvironment targeting for cancer therapy. Topics related to cancer stemness or chemoresistance targeting and so on are welcome.

---

### Guest Editors

Dr. Ming-Wei Lin

1. Department of Medical Research, E-Da Hospital/E-Da Cancer Hospital, Kaohsiung, Taiwan
2. Department of Nursing, College of Medicine, I-Shou University, Kaohsiung, Taiwan

Dr. Cheng-Che Lee

School of Medicine for International Student, I-Shou University, Kaohsiung, Taiwan

---

### Deadline for manuscript submissions

closed (30 April 2023)



## Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/111392](https://mdpi.com/si/111392)

*Current Issues in Molecular  
Biology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cimb@mdpi.com](mailto:cimb@mdpi.com)

[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)





# Current Issues in Molecular Biology

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,  
Christchurch 8140, New Zealand

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.